SLU-PP-332 vs MOTS-c: What the Research Shows
SLU-PP-332 and MOTS-c side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider SLU-PP-332 if…
- you are tested in sport and want to avoid a WADA-prohibited substance: MOTS-c is prohibited by WADA at all times (check SLU-PP-332's own status separately)[2]
Consider MOTS-c if…
- you are weighing human evidence that, in our search, only measured the body's own MOTS-c (none gave it as a treatment): exercise raised plasma MOTS-c in non-Hispanic White survivors but not Hispanic survivors[9]
What they have in common
- Only animal or lab studies of SLU-PP-332 were found (e.g. mouse): In mice, SLU-PP-332 increased energy expenditure and fatty acid oxidation, mimicking exercise effects on whole-body metabolism.[3]
Spec comparison
Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.
| Field | SLU-PP-332 | MOTS-c |
|---|---|---|
| Class | ERR agonist (not a peptide) | Mitochondrial-derived peptide |
| Also called | slupp, SLU-PP | mots |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | PCAC voted 7–5 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized |
| WADA | WADA status unclearSLU-PP-332 is not named. S4.4 lists AMPK activators, PPAR-delta agonists and Rev-erb agonists; SLU-PP-332 is an ERR agonist, which the list does not mention. This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. |
| Anti-doping detection | None reportedanti-doping literature, as of 2 Oct 2026 |
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Animal evidence, 2 of 4Strongest: The Journal of pharmacology and experimental therapeutics 2024, PMID 37739806 | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 7 summarised | 7 human (4 randomized or controlled) of 15 summarised |
| Typical study doses | Not reported in study abstractsPubMed search, 11 Oct 2026 |
|
| Vial sizes sold | 5 mg | 5 mg, 10 mg, 20 mg, 40 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
SLU-PP-332 and MOTS-c together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
Two exercise-mimetic stories, both stopped at the mouse
SLU-PP-332's headline result is metabolic in mice: it raised energy expenditure and fat burning in a way that resembles training.[3]
The ERR agonist SLU-PP-332 reduced obesity and improved insulin sensitivity in models of metabolic syndrome.[3]
MOTS-c improved physical performance in mice aged 2, 12 and 22 months.[19]
In myoblasts, SLU-PP-332 treatment promoted down-regulation of NOX4 and upregulation of SIRT1, PGC-1α, ERRα, FNDC5, Akt and Bcl-2. This is a cell-culture result.[20]
In a human study among non-Hispanic White BCS, post-exercise MOTS-c levels were significantly associated with reductions in fat mass, body weight, HOMA-IR and CRP, and an increase in lean mass (p < 0.01).[9]
Sport status, detection and regulation
MOTS-c is named in the AMPK-activator group on WADA's list.[2]
WADA's catch-all clause is defined by the absence of current approval by a governmental health authority for human therapeutic use.[2]
In a doping-control study of SLU-PP-332, M1, M7, M9, M10, M13, M14, M19 and M20 were the most abundant of 22 metabolites and potentially useful for doping-control purposes.[21]
A Drugs@FDA search for SLU-PP-332 returned no match.[22]
Common questions
SLU-PP-332 vs MOTS-c: which is better?
In mouse models of metabolic syndrome, the ERR agonist SLU-PP-332 reduced obesity and improved insulin sensitivity. The MOTS-c results cited here are in mice and a human biomarker study.[3]
Are SLU-PP-332 and MOTS-c banned in sport?
MOTS-c is named in WADA's AMPK-activator group. SLU-PP-332 is not named in the quoted text; WADA's catch-all clause covers substances without current approval.[2]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3A Synthetic ERR Agonist Alleviates Metabolic Syndrome.The Journal of pharmacology and experimental therapeutics · 2024PMID 37739806Accessed 2 Oct 2026
- 4PubMed search: "SLU-PP-332"[tiab] (10 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: SLU-PP-332[tiab] OR SLU-PP-915[tiab] OR "ERR agonist"[tiab] AND exercise mimetic[tiab] (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 7Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 8Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 9Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND ("SLU-PP-332"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 17PubMed search: ("SLU-PP-332"[tiab] OR "SLU-PP-915"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 18PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 20Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study.Frontiers in physiology · 2025PMID 40692696Accessed 2 Oct 2026
- 21Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes.Drug testing and analysis · 2026PMID 41688415Accessed 2 Oct 2026
- 22Drugs@FDA (openFDA) search: active ingredient "SLU-PP-332"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.